PL3256107T3 - Preparat farmaceutyczny racekadotrylu - Google Patents

Preparat farmaceutyczny racekadotrylu

Info

Publication number
PL3256107T3
PL3256107T3 PL15819831.7T PL15819831T PL3256107T3 PL 3256107 T3 PL3256107 T3 PL 3256107T3 PL 15819831 T PL15819831 T PL 15819831T PL 3256107 T3 PL3256107 T3 PL 3256107T3
Authority
PL
Poland
Prior art keywords
racecadotril
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
PL15819831.7T
Other languages
English (en)
Inventor
Piero Poli
Alessandro FIORINO
Tommaso Roberto PIAZZOLLA
Original Assignee
Rivopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivopharm Sa filed Critical Rivopharm Sa
Publication of PL3256107T3 publication Critical patent/PL3256107T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15819831.7T 2015-02-09 2015-12-23 Preparat farmaceutyczny racekadotrylu PL3256107T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITTO20150086 2015-02-09
PCT/EP2015/081187 WO2016128098A1 (en) 2015-02-09 2015-12-23 Pharmaceutical formulation of racecadotril

Publications (1)

Publication Number Publication Date
PL3256107T3 true PL3256107T3 (pl) 2021-03-22

Family

ID=53002778

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15819831.7T PL3256107T3 (pl) 2015-02-09 2015-12-23 Preparat farmaceutyczny racekadotrylu

Country Status (19)

Country Link
US (1) US10188607B2 (pl)
EP (1) EP3256107B1 (pl)
JP (1) JP6851973B2 (pl)
CN (1) CN107438431B (pl)
AU (1) AU2015382526B2 (pl)
BR (1) BR112017016997A2 (pl)
CA (1) CA2975930A1 (pl)
DK (1) DK3256107T3 (pl)
EA (1) EA035038B1 (pl)
ES (1) ES2822992T3 (pl)
GE (2) GEP20197006B (pl)
HU (1) HUE051692T2 (pl)
IL (1) IL253788A0 (pl)
LT (1) LT3256107T (pl)
PL (1) PL3256107T3 (pl)
PT (1) PT3256107T (pl)
SG (1) SG11201706431SA (pl)
WO (1) WO2016128098A1 (pl)
ZA (1) ZA201705329B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2026905B1 (en) 2020-11-16 2022-06-30 Pharmamatch B V Pharmaceutical granulate formulation and method for the preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914822A4 (en) * 1996-03-14 2002-08-07 Bayer Ag PREPARATION OF ECADOTRIL WITH FAST MICRODISPERSION AND RELEASE
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
FR2900823B1 (fr) 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
CN102166197B (zh) * 2011-04-25 2012-09-05 四川百利药业有限责任公司 消旋卡多曲颗粒及其生产工艺
CN102327234B (zh) * 2011-09-28 2017-04-12 海南康芝药业股份有限公司 一种消旋卡多曲干混悬剂
CN104224724A (zh) * 2013-06-08 2014-12-24 北京韩美药品有限公司 一种消旋卡多曲颗粒剂及其制备工艺
ES2549127T1 (es) * 2014-03-10 2015-10-23 Galenicum Health S.L. Composiciones farmacéuticas que comprenden un principio activo

Also Published As

Publication number Publication date
US20180028448A1 (en) 2018-02-01
CA2975930A1 (en) 2016-08-18
WO2016128098A1 (en) 2016-08-18
GEP20197006B (en) 2019-07-25
JP6851973B2 (ja) 2021-03-31
CN107438431B (zh) 2020-12-15
EA201791794A1 (ru) 2017-12-29
AU2015382526B2 (en) 2020-09-10
SG11201706431SA (en) 2017-09-28
EP3256107B1 (en) 2020-08-12
ZA201705329B (en) 2019-06-26
LT3256107T (lt) 2020-09-25
ES2822992T3 (es) 2021-05-05
AU2015382526A1 (en) 2017-08-24
US10188607B2 (en) 2019-01-29
BR112017016997A2 (en) 2018-04-10
JP2018505208A (ja) 2018-02-22
GEAP201914562A (en) 2019-04-10
IL253788A0 (en) 2017-09-28
CN107438431A (zh) 2017-12-05
EA035038B1 (ru) 2020-04-21
PT3256107T (pt) 2020-09-23
EP3256107A1 (en) 2017-12-20
DK3256107T3 (da) 2020-08-31
HUE051692T2 (hu) 2021-03-29

Similar Documents

Publication Publication Date Title
HUE047477T2 (hu) Palbociclib szilárd dózisformái
SI3769781T1 (sl) Stabilna formulacija proti-IFNAR1
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
PT4070788T (pt) Formulações farmacêuticas
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
MA42303A (fr) Formulations pharmaceutiques
IL256322B (en) Improved formulations of deferasirox and methods of making the same
DK3199161T3 (da) Farmaceutisk præparat
PL3093018T3 (pl) Preparat farmaceutyczny zawierający związki kwasu pirydyloaminooctowego
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
LT3212237T (lt) Metotreksato vaistinė forma
DK3400017T3 (da) Kontinuerlig kompleksering af aktive farmaceutiske ingredienser
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
DK3280447T3 (da) Farmaceutiske formuleringer
IL258630B1 (en) Formulation of l-ornithine phenylacetate
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
HUE069648T2 (hu) Gyógyszerészeti készítmény
HUE058114T2 (hu) Cediranib rögzített idõszakos adagolását tartalmazó eljárások
DK3288967T3 (da) Farmaceutisk forbindelse
HUE050881T2 (hu) Gyógyszerkészítmény
MA43126A (fr) Compositions pharmaceutiques de fumarate de diméthyle
EP3423041A4 (en) PHARMACEUTICAL COMPOSITIONS